Tests darovasertib before surgery or radiation for uveal melanoma
Tests darovasertib given before primary local therapy in adults with uveal melanoma.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Darovasertib in Primary Uveal Melanoma
Key facts
- Where
- Prague 6, CzechiaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with uveal melanoma (a cancer of the eye) that has not spread, who have not yet been treated for it.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Primary uveal melanoma that has not spread (non-metastatic).
- Earlier treatment
- No previous treatment for uveal melanoma.
Main reasons for not taking part
- Previous treatment for uveal melanoma
- Signs that the uveal melanoma has spread
- Eye problems that mean the eye must be removed whatever the response to therapy
- Another worsening eye disease that would confuse the vision tests
- Another cancer besides the one treated in this trial
Read by machine on 9 November 2026.
Where in Czechia
- Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice PrahaPrague 6, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IDEAYA Biosciences
- Trial code
- NCT07015190EU 2025-522387-32-00
- Record updated
- 6 May 2026
- Original description
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)Read full original descriptionShow less
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Inclusion: Primary non-metastatic uveal melanoma; Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements; ECOG 0 or 1; Adequate organ function.
Exclusion: Previous treatment for UM; Attributes that necessitate enucleation regardless of response to therapy; Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments; Presence of a malignant disease other than the one being treated in this study; Evidence of metastatic UM.